At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma
In Brief
A Phase 1 clinical trial evaluating MK-3475, Surgical resection (standard of care), and 5 other interventions for Endometrial Cancer and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.